Navigation Links
SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
Date:9/20/2011

MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire/ -- SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. The study is taking place at the University of Pittsburgh Medical Center. An additional study site is also open and recruiting patients at the Stanford University Medical Center in Palo Alto, CA.

SB623 has been shown to improve neurological behavior in preclinical models of stroke. In this study, safety and efficacy parameters will be evaluated, including improvements in motor function and cognitive status. The trial will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.

"We are excited to be a part of this important new study offering a novel approach to therapy for patients suffering from ischemic stroke disability," said Douglas Kondziolka, MD, Peter J. Jannetta professor and vice chairman of neurological surgery at the University of Pittsburgh Medical Center (UPMC), and Principal Investigator of the study.

"Preclinical models have shown that SB623 restores function in animal models of stroke. With over seven million stroke victims in the U.S. today, we are eager to explore the potential of SB623 in patients who may otherwise be permanently disabled," said Lawrence Wechsler, MD, chair, department of neurology at UPMC.

"With two trial sites now open, our goal is to explore the potential of SB623 as a potential treatment for stroke disability as rapidly as possible," said Keita Mori, Co-CEO of SanBio. "SB623 represents a significant step forward in the development of regenerative therapies."

For more information on the SB623 trial, please visit www.strokeclinicaltrial.org.

About SB623
SB623 is a proprietary regenerative cell therapy consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 functions by producing proteins that aid the healing process.

About SanBio
SanBio is a leader in the discovery and development of new regenerative cell therapy products. The company's first product, SB623, is currently in a Phase 1/2a clinical trial for stable stroke patients. In addition to SB623, SanBio is using its proprietary technology to develop programs in Parkinson's disease, spinal cord injury and traumatic brain injury. For more information, please visit san-bio.com.


'/>"/>
SOURCE SanBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
2. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):